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Abstract
The PI3K pathway is one of the most commonly misregulated signaling pathways in human
cancers, but its impact on the tumor microenvironment has not been considered as deeply as its
autonomous impact on tumor cells. In this study we demonstrate that NF-κB is activated by the
two most common PI3K mutations, PIK3CA E545K and H1047R. We found that markers of NF-
κB are most strongly upregulated under conditions of growth factor deprivation. Gene expression
analysis performed on cells deprived of growth factors identified the repertoire of genes altered by
oncogenic PI3K mutations following growth factor deprivation. This gene set most closely
correlated with gene signatures from claudin-low and basal-like breast tumors, subtypes frequently
exhibiting constitutive PI3K/Akt activity. An NF-κB-dependent subset of genes driven by
oncogenic PI3K mutations was also identified that encoded primarily secreted proteins, suggesting
a paracrine role for this gene set. Interestingly, while NF-κB activated by oncogenes such as Ras
and EGFR leads to cell-autonomous effects, abrogating NF-κB in PI3K-transformed cells did not
decrease proliferation or induce apoptosis. However, conditioned media from PI3K mutant-
expressing cells led to increased STAT3 activation in recipient THP-1 monocytes or normal
epithelial cells in a NF-κB and IL-6-dependent manner. Together, our findings describe a PI3K-
driven, NF-κB-dependent transcriptional profile which may play a critical role in promoting a
microenvironment amenable to tumor progression. These data also indicate that NF-κB plays
diverse roles downstream from different oncogenic signaling pathways.
Introduction
Phosphatidylinositol 3-kinase (PI3K) is an essential mediator of cellular processes critical to
tumorigenesis such as growth, survival, and cell proliferation (1, 2). Consistent with these
roles, the PI3K pathway is one of the most commonly misregulated signaling pathways in
human cancers and the PI3K catalytic subunit (p110α, PIK3CA) itself is frequently
amplified or mutated in cancer (2–5). In fact, about 30% of breast cancer samples harbor
mutations in PIK3CA (3, 6), of which the most common are E545K and H1047R. These
sites lie in mutational hotspots that account for >85% of oncogenic PIK3CA mutations (3,
6). Tissue-specific expression of the H1047R mutation in transgenic mice leads to both
breast and lung tumors (7–9). In addition, both the E545K and H1047R mutations induce
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cell transformation characterized by growth factor independent AKT signaling and
proliferation, as well as colony growth in soft agar, when expressed in a variety of cell types,
including MCF10A cells (10–12).
The IKK/NF-κB pathway is a critical signaling axis which regulates diverse cellular
functions such as inflammation, cell survival, proliferation, and senescence (13–15).
Canonical NF-κB activation requires activation of the IκB kinase (IKK) complex, which
phosphorylates the NF-κB inhibitory protein IκB, leading to IκB proteasomal degradation
and nuclear accumulation of activated NF-κB heterodimers (14). NF-κB DNA binding is
greatly enhanced by phosphorylation of the NF-κB subunit p65. NF-κB is frequently
activated in a variety of solid tumors including melanoma and breast, prostate, and liver
tumors (16–18). In addition, a number of oncogenic signaling pathways, such as Ras, EGFR,
and HER2, depend on NF-κB for full transformation potential (19–23). NF-κB activities
involved in oncogenesis are hypothesized to result from transcriptional upregulation of a
large number of well-characterized anti-apoptotic and pro-proliferation NF-κB target genes.
However, no comprehensive oncogenic NF-κB-dependent transcriptional profile has been
identified.
IL-6 is a well-established NF-κB target gene and a critical inflammatory mediator, as its
secretion potently activates T cells and macrophages (24). However, IL-6 is also associated
with increased cancer cell proliferation and tumor progression (24, 25). In fact, expression
of IL-6 in the serum or tissue of cancer patients correlates with poor prognosis (24, 25).
Binding of IL-6 to its receptor activates JAK tyrosine kinases, which promote
phosphorylation and nuclear translocation of STAT3 transcription factors. Many tumor
types such as breast, colon, lung, and prostate, are characterized by increased STAT3
activation (26–28).
Here, we use MCF10A cells expressing PIK3CA E545K or H1047R to show that NF-κB is
activated by these oncogenic mutations. Interestingly, while modest NF-κB activation was
identified under growth conditions, markers of NF-κB activation were most dramatically
increased under conditions of growth factor (GF) deprivation. While GF-independent
signaling and proliferation are well-established hallmarks of cancer (29), few studies of
cancer cells are performed under conditions of GF deprivation, and little is known regarding
GF-independent gene expression changes occurring downstream from oncogenes. We
therefore identified both a comprehensive transcriptional profile and an NF-κB-dependent
gene set activated by the E545K and H1047R mutations. NF-κB activity downstream from
EGFR and Ras plays an important role in cancer cell survival and proliferation (19, 20, 23).
In contrast, we show that NF-κB activity driven by oncogenic PIK3CA mutations does not
increase proliferation, survival, or anchorage-independent growth of the transformed cells.
Rather, the primary function of PI3K-driven NF-κB activation is to promote expression and
secretion of cytokines and chemokines, especially IL-6, which act in a paracrine and
autocrine manner to activate STAT3 in nearby monocytes and normal epithelial cells.
Together, these data support a model in which PI3K-driven NF-κB activation leads to
increased activation of nearby stromal cells, helping to generate a pro-tumor
microenvironment and facilitate tumor progression. In addition, these data suggest the
exciting possibility that the role of NF-κB may vary dramatically downstream from different
oncogenes and under different growth/growth factor conditions.
Materials and Methods
Antibodies, Plasmids, and Reagents
pJP1520-HA-GFP, pJP1520-HA-PIK3CA WT, pJP1520-HA-PIK3CA E545K, and p-
JP1520-HA-PIK3CA H1047R, were a generous gift from Dr. Lewis Cantley (10). Anti-
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Phospho-AKT, anti-phospho-ERK, anti-phospho-p65, anti-phospho-IKK, anti-phospho-
IκBα, anti-phospho-STAT3, anti-AKT, anti-p65, anti-IκBα, and anti-STAT3 were from
Cell Signaling Technology. Anti-HA was from Covance. Anti-Actin was from Abcam.
TaqMan real-time RT-PCR gene expression assays were from Applied Biosystems. IL-6
ELISA assays were from BD Biosciences. CXCL1 ELISA assays and the IL-6 receptor
monoclonal antibody were from R&D Systems. LY294002 and UO126 were obtained from
Cell Signaling Technology. BAY-65-1942 was from Bayer Pharmaceuticals.
Microarray Analysis
Total RNA was purified, reverse-transcribed, labeled, and hybridized to a custom Agilent
4X44K whole human DNA microarray as described previously (30). Microarrays were
scanned using an Agilent DNA microarray scanner and features were extracted using
Agilent Feature Extraction software version 10.7.3.1. Data was uploaded to the University
of North Carolina Microarray Database (UMD) and to the Gene Expression Omnibus (GEO)
under accession number GEO:GSE33403. Gene expression data was extracted from the
UMD for each sample as log2 Cy5/Cy3 ratios, filtering for probes with Lowess normalized
intensity values greater than 10 in both channels and for probes with data on greater than
70% of the microarrays. Hierarchical clustering was performed using Gene Cluster 3.0 (31)
and data was viewed using Java Treeview version 1.1.5r2 (32). Expression changes were
determined using a 1-Class significance analysis of microarray (SAM) analysis for each
experimental set of conditions using the maximum number of permutations (33). In each
case, on a single microarray, GFP control was compared to PIK3CA WT, PIK3CA E545K,
or PIK3CA H1047R. Probes with a false discovery rate (FDR) of 0% were considered
statistically significant. Categorical enrichment of the top 300 PIK3CA mutant induced
genes (based on average fold-change) was determined using EASE version 2.0 with all
genes found in the final dataset used as the background population list (34). Categories with
a Bonferonni corrected p-value ≤ 0.05 were considered statistically significant.
Cell Culture and Western Blotting
MCF10A cells and THP-1 cells were purchased from ATCC and used for no longer than 6
months before being replaced. MCF10A cells expressing GFP, PIK3CA WT and mutants
were generated and grown as described previously (10, 35). For starvation experiments, cells
were grown for 24h in complete media lacking EGF and insulin, as described previously
(10). For all Western blots, cells were lysed in RIPA buffer with protease and phosphatase
inhibitors.
Soft Agar Assays
MCF10A cells expressing PIK3CA WT, E545K, or H1047R were infected with adenovirus
expressing either GFP or IκBα superrepressor at 10 MOI overnight. Media was removed,
and cells were allowed to recover in growth media for 24h. Infected cells were then plated in
0.6% Bacto Agar in the absence of growth factors. Media was replaced every 4 days.
Colonies were counted after 25 days.
Results
NF-κB is activated in PI3K-transformed cells following growth factor deprivation
To determine whether the IKK/NF-κB signaling pathway is activated downstream from
PIK3CA mutations, MCF10A cells stably expressing GFP (control), HA-PIK3CA WT, HA-
PIK3CA E545K, or HA-PIK3CA H1047R were propagated in normal growth media (G),
starvation media lacking EGF and insulin for 24h (−), or starvation media for 24h followed
by 10 minutes of EGF and insulin stimulation (+) (Figure 1A and quantified in Figure S1).
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PIK3CA E545K and H1047R expression was higher than WT PIK3CA expression,
consistent with previous studies demonstrating that these mutations confer resistance to
proteasome-mediated degradation (36). In addition, total levels of AKT, p65, and IκBα
were slightly increased in cells expressing E545K or H1047R. Under growth conditions
cells expressing the E545K or H1047R mutations exhibited slightly increased
phosphorylation of AKT and the NF-κB markers p65 and IκBα, when compared to cells
expressing GFP or WT PIK3CA. It is well-established that WT MCF10A cells require
exogenous EGF and insulin in order to proliferate, even in the presence of serum, while
transformed MCF10A cells can undergo growth-factor independent proliferation (10).
Consistent with this, following 24h of growth factor deprivation, cells expressing the
oncogenic mutations exhibited dramatically increased AKT phosphorylation compared to
cells expressing GFP or WT PIK3CA. Interestingly, under conditions of GF deprivation
cells expressing the oncogenic mutations also demonstrated dramatically increased
phosphorylation of p65 and IκBα (Figure 1A). However, surprisingly, while stimulating
these GF-deprived cells with EGF and insulin led to increased AKT phosphorylation, p65
and IκBα phosphorylation rapidly and dramatically decreased (Figure 1A). While it is not
clear how NF-κB is being so acutely downregulated following growth factor stimulation,
these data suggest that NF-κB is not being regulated via a direct signaling pathway
downstream from AKT.
A comprehensive profile of genes upregulated by PIK3CA mutations has not been
described. Therefore, we utilized microarrays to identify both global and NF-κB-dependent
gene expression changes that occur in PI3K-transformed cells following GF deprivation.
Supervised gene expression analyses were performed to find genes changed by the ectopic
expression of mutant and WT PIK3CA. As expected, expression of WT PIK3CA led to few
gene changes when compared to cells expressing GFP control (Figure 1B). However,
expression of PIK3CA E545K or H1047R led to a statistically significant change in
expression (based on SAM analysis) for 5513 genes, of which 1290 changed more than 2-
fold (Figure 1B and Supplemental Table 1), suggesting that a large number of transcriptional
programs are dramatically altered downstream from oncogenic PI3K mutations. While both
the E545K and H1047R mutations increase the lipid kinase activity of PI3K, they act via
different mechanisms (10, 11). However, our transcriptional analysis of these two mutations
revealed that no statistically significant changes exist between the E545K and H1047R
mutations when transcription of individual genes is examined (Figure 1B). For this reason,
in later analyses we combine the gene expression data for the E545K and H1047R mutations
and perform common analyses. Interestingly, a categorical enrichment analysis revealed that
many of the gene categories statistically enriched by oncogenic PI3K mutations are known
to be regulated by NF-κB, such as chemokine, inflammatory, and immune signaling
pathways (Figure 1C). These data are consistent with Figure 1A, and suggest a critical role
for inflammation in promoting growth factor-independent survival and tumorigenicity of
PI3K-driven cancers.
We next sought to determine what subset of genes upregulated by oncogenic PI3K is
dependent on IKK/NF-κB signaling. Cells expressing the E545K or H1047R mutation were
treated with DMSO or the well-established IKKβ-specific inhibitor BAY-65-1942 (BAY)
for 4 hours (37). Phosphorylation of p65 and IκBα was completely abrogated following
treatment with BAY-65-1942 (Figure 2A). Interestingly, phosphorylation of AKT and
protein levels of both p65 and AKT were also slightly decreased, suggesting that expression
and/or stability of these proteins may be partially NF-κB-dependent. Microarrays revealed
that 48 genes are both upregulated in the presence of PI3K mutation and downregulated
following 4 hours of IKKβ inhibition (Figure 2B and Supplemental Table 1). Many of these
are established NF-κB target genes, while several are putative NF-κB targets which were
previously unknown. Expression of several of these genes was validated by real-time RT-
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PCR (Figures 2C–D and Figure S2) and ELISA (Figures 2E–F, Figure S3). Expression of
the PI3K-dependent, but NF-κB-independent, genes ENPP2 and S100A8 was also examined
(Figure S2). Together, the data in Figures 1 and 2 show that both IKK signaling and NF-κB
target gene expression are dramatically upregulated in cells expressing oncogenic PI3K
mutations.
Sustained activation of signaling pathways in PI3K-transformed cells following PI3K
inhibition
In order to determine whether inhibition of PI3K with LY294002 can disrupt IKK signaling
in PI3K-transformed cells, MCF10A cells expressing the E545K or H1047R mutations were
GF-deprived for 24 hours and treated with LY294002 for 30 or 120 minutes (Figure 3A).
Interestingly, while AKT phosphorylation was completely abrogated following 30 minutes
of LY294002 treatment, these short treatments with the PI3K inhibitor did not decrease
phosphorylation of p65. In contrast, long (10h or 24h) periods of PI3K inhibition led to
dramatically decreased phosphorylation of p65, IκBα, and IKK (Figure 3B and 4A). Further
examination suggested that other stress-responsive signaling pathways, such as ERK and
p38, are activated in the presence of the PI3K mutants following GF deprivation and showed
sustained activation following PI3K inhibition (Figure 3B). These observations led us to
perform further microarray analyses to identify gene expression changes following short
(4h) or long (24h) treatment with LY294002 (Figure 4A). Consistent with our signaling
data, of the 2856 genes upregulated by PI3K mutation, 405 were decreased following 4h of
PI3K inhibition, and 740 genes were decreased following 24h of PI3K inhibition (Figure
4B). An examination of the NF-κB-dependent subset of genes showed that of the 48 NF-κB
target genes upregulated by PIK3CA mutations, 10 were decreased following 4h PI3K
inhibition, while 35 were decreased following 24h PI3K inhibition (Figure 4C). Expression
of several of these genes, including IL-6 and CXCL1, was verified by real-time RT-PCR
(Figure 4D–E). These results demonstrate that, following GF deprivation, oncogenic PI3K
mutations activate a large number of long-lived signaling pathways and transcriptional
complexes which are not appropriately feedback-inhibited.
NF-κB is not required for proliferation, survival, or anchorage-independent growth of PI3K-
transformed cells
NF-κB target genes are critical for a wide range of cellular processes known to be required
for tumorigenesis, such as proliferation, resistance to apoptosis, and response to cellular
stress such as hypoxia (15, 16). Surprisingly, IKK inhibition did not decrease proliferation
or metabolic activity of growth-factor deprived transformed MCF10A cells as assessed by
MTT assay (Figures 5A and S4A). In addition, the IKK inhibitor did not synergize with a
PI3K and/or MEK inhibitor to further decrease cell growth or increase PARP cleavage in
PI3K-transformed cells (Figures 5A–B and S4A–B). An unphosphorylatable IκBα isoform
(S32A/S36A) acts as an NF-κB “superrepressor” which prevents nuclear translocation of
NF-κB. Expression of this NF-κB superrepressor in PI3K-transformed MCF10A cells failed
to decrease colony formation in soft agar under GF-independent conditions (Figure 5C).
Together, these data indicate that the primary function of NF-κB downstream from
oncogenic PI3K mutations is not cell-autonomous. Rather, we observed that a large number
of the NF-κB dependent genes upregulated by PI3K mutation are cytokines, chemokines,
and other secreted proteins (Figure 2B). Therefore, we hypothesized that the role of NF-κB
in PI3K-driven cell transformation may be to activate surrounding stromal and inflammatory
cells in a paracrine (and autocrine) manner.
Hutti et al. Page 5










Secreted NF-κB gene products from PI3K-transformed cells activate STAT3 in monocytes
and epithelial cells
Many advanced tumors are characterized by infiltration of macrophages and other immune
cells to the site of the tumor. In order to determine whether factors secreted from PI3K-
transformed cells can activate immune cells, conditioned media experiments were
performed. MCF10A cells expressing GFP, PIK3CA E545K, or PIK3CA H1047R were
deprived of growth factors for 24h. THP-1 monocytes were then resuspended in conditioned
media from these cells to allow factors present in the media to activate the THP-1 cells.
Interestingly, no phosphorylation of p65 was observed in recipient THP-1 cells, suggesting
that no factors secreted by the PI3K-transformed cells activate NF-κB (Figure 5D).
However, THP-1 cells treated with the media from E545K or H1047R-expressing cells
showed robust activation of STAT3 and ERK in as little as 5 minutes. In addition,
conditioned media from growth factor-deprived MCF10A cells expressing the E545K or
H1047R mutations dramatically increased STAT3 phosphorylation in parental MCF10A
cells within 30 minutes, suggesting that a factor(s) secreted by PI3K-transformed cells can
also activate STAT3 signaling in normal epithelial cells (Figures 5E–F). Pretreating donor
PI3K-transformed cells with an IKK inhibitor for 24h prior to stimulating either THP-1 cells
or MCF10A cells with conditioned media led to a dramatic decrease in STAT3
phosphorylation, showing that the cytokine(s) activating STAT3 are being expressed in an
NF-κB -dependent manner (Figure 6A–B and S5A–B).
IL-6 is required for E545K and H1047R-driven paracrine effects
IL-6 is a well-established pro-tumorigenic cytokine that activates STAT3 and ERK, the two
signaling pathways which were activated in THP-1 cells by E545K or H1047R conditioned
media. IL-6 is also one of the NF-κB target genes most dramatically upregulated in PI3K-
transformed cells (Figures 2C and 2E). Therefore, we hypothesized that IL-6 may be the
primary cytokine involved in these paracrine activities. Consistent with this, pretreating
recipient MCF10A or THP-1 cells with an IL-6 receptor antagonizing monoclonal antibody
for 2h prior to adding conditioned media from GF-deprived transformed MCF10A cells
dramatically decreased STAT3 phosphorylation compared to cells pretreated with a control
antibody (Figure 6C–D and S5C–D). Together, data in Figures 5 and 6 indicate that one of
the primary consequences of NF-κB activation in PI3K-transformed cells is increased
expression of IL-6, which can then activate STAT3 in both normal epithelial cells and
immune cells in a paracrine manner.
The ability to stimulate parental MCF10A cells in a paracrine manner suggests that IL-6
may also activate STAT3 in an autocrine manner. Indeed, Figure 6E shows that STAT3
phosphorylation is increased in cells expressing the oncogenic PI3K mutations.
Interestingly, total STAT3 protein levels are also increased. In addition, treating PI3K-
transformed cells with an IKK inhibitor or PI3K inhibitor for short periods of time (<1h)
does not affect phosphorylation of STAT3, consistent with an autocrine loop rather than
direct intracellular signaling (Figures 6F–G, S5E–F, and data not shown). However, longer
(24h) periods of IKK or PI3K inhibition do lead to decreased STAT3 phosphorylation,
consistent with our microarray and real-time RT-PCR data showing that IL-6 is decreased at
this timepoint. Treating PI3K-transformed MCF-10A cells with an IL-6R antagonizing
antibody leads to decreased STAT3 phosphorylation, though this is not sufficient to decrease
cell proliferation. These data are consistent with a model in which the primary role of PI3K-
activated NF-κB is to induce paracrine activation of surrounding stromal cells (Figures
S6A–B).
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The PIK3CA mutant gene signature correlates with claudin-low and basal breast cancer
subtypes
It has become clear over the last decade that breast cancer is not a single disease, but, rather,
a set of diseases which can be classified into a variety of subtypes identified using protein or
gene expression patterns (38, 39). The clinical relevance of these subtypes has been well-
established, as different breast cancer subtypes display differences in patient survival and
response to therapies (38, 39). It is therefore of great interest to determine which breast
cancer subtype our PIK3CA-driven transformed cells resemble. As MCF10A cells are
hormone receptor-negative, we hypothesized that transformed MCF10A cells might most
closely resemble triple-negative, basal-like breast cancer (35, 40). Triple-negative breast
cancers frequently display increased activation of the PI3K pathway, usually due to loss of
either the PTEN or INPP4B tumor suppressors, and sometimes due to PIK3CA mutation (5,
41–45). We first identified the top 300 genes which are upregulated by PI3K mutation in
MCF10A cells, which we refer to as the PIK3CA mutant gene signature. Of these, 192
probes correspond to those present in the publicly available UNC337 dataset which provides
comprehensive gene expression and subtype data for 337 breast tumors. Gene expression
data for these 192 probes was then evaluated within the UNC337 dataset using hierarchical
clustering analysis (Figure 7A). Consistent with our hypothesis, the PIK3CA mutant gene
signature most closely correlated with the triple-negative claudin-low and basal-like
subtypes (Figure 7B). Interestingly, claudin-low tumors are also characterized by
enrichment of immune response genes, including CCL2, CXCL2, and IL-6, which were also
identified in our PIK3CA mutant gene signature (30, 39). MCF10A cells transformed by
oncogenic PI3K mutations therefore provide an in vitro model that properly recapitulates
both the signaling and gene expression profiles which occur in vivo in triple-negative
tumors, many of which have constitutive PI3K activation.
Discussion
Cancer cells are characterized by the ability to proliferate in the absence of growth factors,
but it is unclear what effects GF deprivation has on gene transcription downstream from
oncoproteins. Here, we show that NF-κB signaling and gene expression are strongly
upregulated under conditions of growth factor deprivation in PI3K-transformed cells, and
categorical enrichment analysis showed that a number of cellular processes dependent on the
transcription factor NF-κB are dramatically increased by these mutations (Figures 1C).
Interestingly, we also observed that while stimulating these GF-deprived cells with EGF and
insulin led to the expected increase in AKT phosphorylation, p65 and IκBα phosphorylation
rapidly and dramatically decreased (Figure 1A). While it is not clear how NF-κB is being so
acutely regulated under conditions of growth factor deprivation or stimulation, this
disconnect between AKT phosphorylation and p65 phosphorylation suggests that NF-κB is
not being activated via a direct signaling pathway downstream from AKT. Rather, we
hypothesize that in the setting of a tumor, NF-κB is activated as part of a stress response to
the aberrant cancer cell proliferation in the absence of growth factors. Once the stress is
relieved by stimulation with growth factors, NF-κB is no longer required and is rapidly
deactivated.
NF-κB can regulate any of hundreds of target genes depending on the type of stimulus,
duration of stimulus, and the type of cell being activated (46). Interestingly, microarray
analysis revealed that of the genes upregulated by oncogenic PI3K mutations, 48 were then
downregulated following 4h treatment with an IKK inhibitor, providing a comprehensive
NF-κB-dependent oncogenic transcriptional profile. Previous studies demonstrating a role
for NF-κB downstream from oncogenes such as KRAS or EGFR have shown that the effects
of NF-κB are largely cell-autonomous. In contrast, we find that inhibiting NF-κB in PI3K-
transformed cells transformed does not lead to decreased cell proliferation, increased
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susceptibility to apoptosis, or decreased colony growth in soft agar (Figures 5A–C and S4).
These data suggest the interesting possibility that even though numerous oncogenes may
activate NF-κB, the set of NF-κB target genes that are transcribed may vary enormously
between different cancers and under different growth/growth factor conditions.
Virtually all of the PI3K-driven NF-κB target genes identified by the microarray analyses
are cytokines, chemokines, or other secreted proteins. Of these genes, IL-6 was of particular
interest as it is highly expressed in PI3K-transformed cells in an NF-κB-dependent manner,
and because its importance in tumorigenesis is well-established. Indeed, we find that
conditioned media from cells expressing the E545K or H1047R mutations can dramatically
upregulate STAT3 phosphorylation in both THP-1 monocytes and normal MCF10A breast
epithelial cells in an NF-κB and IL-6 dependent manner (Figures 5–6). While the effect of
this increased STAT3 activation will need to be confirmed in an in vivo model of PI3K-
driven tumorigenesis, it is clear that increased macrophage infiltration and stromal
inflammation correlates with poor prognosis in a number of tumor types. In addition,
inhibition or genetic loss of STAT3 decreases progression of epithelial tumors in several
animal models (26–28). We therefore propose that addition of an IL-6 receptor inhibitor,
such as the recently FDA-approved tociluzimab, may dramatically increase the effectiveness
of treatment regimens for PI3K-driven tumors by decreasing immune cell infiltration to the
site of the tumor.
For virtually all solid tumors, the tumor microenvironment plays a critical role in the
survival and progression of the tumor by influencing invasion, metastasis, angiogenesis, and
recruitment of tumor-supporting macrophages (15, 47). While many signaling pathways
regulate these stromal effects, the NF-κB pathway is well-positioned to be a critical
regulator of virtually all of these processes as many of the proteins which regulate these
diverse pathways are known NF-κB target genes (15, 16). Several recent reports have
demonstrated that cells transformed by oncogenes such as Ras, EGFR, or HER2 lead to
activation of NF-κB (19–23). These groups also demonstrated that inhibition of NF-κB in
these transformed cells decreases proliferation and/or increases the susceptibility of cells to
apoptosis in a largely cell-autonomous manner. However, non-cell autonomous roles for
NF-κB in manipulating the tumor microenvironment have been less well-studied in these
cancer models. Interestingly, a recent study by Ying, et al. showed that while KRAS
mutation is sufficient to induce pancreatic ductal adenocarcinoma, additional loss of PTEN
drives increased cytokine production and immune cell infiltration to the site of the tumor
(48). However, this group also demonstrated a cell autonomous role for NF-κB (48). As
RAS mutation alone has been shown to increase cell proliferation in an NF-κB-dependent
manner (19, 21, 23), it is possible that KRAS mutation leads to NF-κB-driven expression of
genes which promote proliferation, while additional activation of PI3K leads to a different
NF-κB-driven cytokine and chemokine profile. Alternatively, as NF-κB can activate unique
gene sets when in a complex with other transcription factors it is possible that KRAS-
mediated ERK signaling leads to activation of transcription factors, such as AP-1, which
cooperate with NF-κB to activate a different gene set than that observed in the presence of
KRAS alone. It is therefore clear that while numerous oncogenes may all converge on NF-
κB, it will be critical to define the gene sets regulated by NF-κB downstream from these
various oncogenes in order to determine the effect of this NF-κB activity and to predict how
interplay between NF-κB and other oncogenic signaling pathways may promote tumor
growth.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. IKK/NF-κB is activated by oncogenic PI3K mutations
MCF10A cells stably expressing HA-GFP, HA-PIK3CA WT, HA-PIK3CA E545K, or HA-
PIK3CA H1047R were generated by retroviral transduction. A) Cells were grown in growth
medium (G), starvation medium lacking EGF and insulin (−) for 24h, or were starved for
24h and stimulated for 10 minutes with 20ng/mL EGF and 10μg/mL insulin (+). Lysates
were evaluated by immunoblot. B) Cells expressing PIK3CA WT, E545K, or H1047R were
GF-deprived for 24h. RNAs were evaluated by microarray and compared to expression in
GFP control samples. Genes which are statistically significant by SAM analysis and altered
more than 2-fold are shown in the heat map. Color key is for log2 ratio. C) A categorical
enrichment analysis was performed on the top 300 genes upregulated by the E545K or
H1047R mutation. Statistically enriched categories are shown (P < 0.05).
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Figure 2. NF-κB target genes are upregulated by oncogenic PI3K mutations
MCF10A cells stably expressing GFP, PIK3CA WT, E545K, or H1047R were starved for
24h and treated with DMSO or 2μM BAY-65-1942 for 4h. A) Cells were lysed and
evaluated by immunoblot. B) Microarray analysis was performed. Genes which exhibit both
increased expression in PIK3CA-transformed cells and decreased expression following IKK
inhibition are shown. C–D) Real-time RT-PCR was used to verify expression changes for
IL-6 and CXCL1. E–F) ELISA analysis shows increased secretion of IL-6 and CXCL1 by
cells expressing the oncogenic PI3K mutations following 24h GF-deprivation.
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Figure 3. Sustained PI3K inhibition decreases NF-κB activation by oncogenic PI3K mutations
A) MCF10A cells stably expressing GFP, PIK3CA WT, E545K, or H1047R were starved
for 24h, treated with 20μM LY294002 for 0–120 minutes and lysates were evaluated by
immunoblot. B) MCF10A cells stably expressing GFP, PIK3CA WT, E545K, or H1047R
were starved for 24h, treated with 20μM LY294002 for 0–10h and lysates were evaluated
by immunoblot for the indicated signaling molecules.
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Figure 4. Sustained PI3K inhibition decreases expression of NF-κB target genes in cells
expressing oncogenic PI3K mutations
A) MCF10A cells expressing PIK3CA H1047R were treated for 4h or 24h with 10μM
LY294002 and analyzed by immunoblot. B) RNA samples from cells treated as in A) were
evaluated by microarray. C) Venn diagram depicting changes in NF-κB-dependent gene
expression following 4h or 24h of LY294002 treatment. C–D) MCF10A cells expressing
PIK3CA E545K were treated for 4h or 24h with 10μM LY294002 and analyzed by real-
time RT-PCR to evaluate expression of C) IL-6 or D) CXCL1.
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Figure 5. Secreted factors from cells expressing oncogenic PI3K mutations activate STAT3
A) GF-deprived MCF10A cells expressing PIK3CA H1047R were treated for 3 days with
the indicated inhibitors. Media and inhibitors were replaced daily. BAY = 2μM
BAY-65-1942. LY = 10μM LY294002. UO = 10μM UO126 and cells were evaluated by
MTT assay. B) Growth factor-starved MCF10A cells expressing H1047R were treated for 2
days with the indicated inhibitors. Media and inhibitors were replaced daily. Lysates were
evaluated for PARP cleavage. 1μM staurosporine (positive control) was added 6h prior to
lysis. C) MCF10A cells expressing PIK3CA WT, E545K, or H1047R were infected with
adenovirus expressing either GFP or IκBα superrepressor (SR) and plated in 0.6% Bacto
agar in MCF10A media lacking EGF and insulin. Colonies were counted after 25 days. D)
MCF10A cells expressing GFP, PIK3CA E545K, or PIK3CA H1047R were starved for 24h.
Conditioned media from these cells was used to treat THP-1 monocytes for 0–60 minutes.
Lysates were evaluated by immunoblot. E–F) MCF10A cells stably expressing PIK3CA
E545K (E) or H1047R (F) were starved for 24h. Conditioned media from these cells was
then used to stimulate starved parental MCF10A cells for 0–120 minutes. Lysates were
evaluated by immunoblot.
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Figure 6. IL-6 contributes to STAT3 activation by E545K or H1047R conditioned media
A) MCF10A cells stably expressing PIK3CA E545K or H1047R were starved for 24h in the
presence or absence of 2μM BAY-65-1942. Conditioned media was used to stimulate
parental MCF10A cells for 30 min and lysates were evaluated by immunoblot. B) MCF10A
cells expressing GFP, PIK3CA E545K, or PIK3CA H1047R were starved for 24h in the
presence or absence of 2μM BAY-65-1942. Conditioned media was used to stimulate
THP-1 cells for 15 minutes and lysates were evaluated by immunoblot. C) Donor MCF10A
cells expressing PIK3CA E545K or H1047R were starved for 24h. Both recipient parental
MCF10A cells and donor cells were pretreated for 2h with 500 ng/mL IL-6 receptor
antagonizing antibody or conrol antibody (anti-Flag mouse monoclonal). Conditioned media
from donor cells was used to stimulate parental MCF10A cells for 30 minutes and lysates
were evaluated by immunoblot. D) Donor MCF10A cells expressing GFP, PIK3CA E545K,
or PIK3CA H1047R were starved for 24h. Recipient THP-1 cells and donor cells were
pretreated for 2h with 500 ng/mL IL-6 receptor antagonizing antibody or control antibody
(anti-Flag mouse monoclonal). Conditioned media from donor cells was used to stimulate
THP-1 cells for 15 minutes and lysates were evaluated by immunoblot. E) MCF-10A cells
expressing GFP, or PIK3CA WT, E545K, or H1047R were GF-deprived for 24h and
immunoblotted with the indicated antibodies. F–G) MCF10A cells expressing PIK3CA
H1047R were GR-deprived for 24h and treated for the indicated times with F) 2μM
BAY-65-1942 or G) 10μM LY294002 and immunoblotted with the indicated antibodies.
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Figure 7. The PIK3CA mutant gene signature correlates with claudin low and basal breast
cancer subtypes
A) 192 of the top 300 genes upregulated by PIK3CA mutation were identified in the
UNC337 dataset. Expression of these genes is shown for each of the breast tumor samples
present in the UNC337 dataset. Color-coding denotes tumor subtype: basal-like (red);
claudin-low (yellow); HER2-enriched (pink); luminal A (dark blue); luminal B (light blue);
normal breast-like (green). B) The expression value for each of the 192 PIK3CA
upregulated genes was plotted by subtype and average signature value was calculated.
Colored dots or boxes denote tumor subtype. BL (red), basal-like; CL (yellow), claudin-low
H2 (pink), HER2-enriched; LA (dark blue), luminal A; LB (light blue), luminal B; NBL
(green), normal breast-like.
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